Literature DB >> 12515999

Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.

Derya Gümürdülü1, E Handan Zeren, Philip T Cagle, Fazilet Kayasel uk, Nazan Alparslan, Ali Kocabas, Ilhan Tuncer.   

Abstract

Histological diagnosis of malignant mesothelioma (MM) and differentiation from adenocarcinoma is often difficult. A number of clinical, radiologic, histologic and histochemical criteria have been used as diagnostic aids, but most cases cannot be readily classified on the basis of these characteristics. In recent years, a panel of immunohistochemical anti-bodies have been increasingly applied for the differential diagnosis of these two tumors. MOC-31 has been recently used as specific for adenocarcinomas while reacting with a minimal number of benign and malignant mesothelial proliferations, and HBME-1 has also been presented as a mesothelial cell marker. In this study, we aimed to show the importance of these two antibodies among the environmental MM cases from Southeastern Turkey. Fifty five cases of MM and twenty adenocarcinomas were included in this study. Histochemical (PAS, PAS-D, mucicarmine) and immunohistochemical (Keratin, EMA,CEA, MOC-31, HBME-1) stains have been performed on each case. Keratin was positive in all cases. EMA stained 50 of 55 MM and all the adenocarcinoma cases. According to our results, dPAS, mucicarmen, CEA and MOC-31 positivity was statistically significant in the diagnosis of adenocarcinoma whereas HBME-1 was demonstrable in most MM cases (52/55) and 11 adenocarcinoma cases. This study confirmed that in the diagnostic distinction between MM and adenocarcinoma, immuno-histochemistry is an important diagnostic tool, however, a panel of antibodies must be used rather than any single antibody. HBME-1 should be included in this panel; MOC-31 can be used where CEA is not available or to doublecheck the reactivity of this antibody.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12515999     DOI: 10.1007/bf03032393

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  26 in total

1.  HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura.

Authors:  A D Kennedy; G King; K M Kerr
Journal:  J Clin Pathol       Date:  1997-10       Impact factor: 3.411

2.  Immunohistochemical differentiation of sarcomatoid mesotheliomas from other spindle cell neoplasms.

Authors:  P T Cagle; L D Truong; V L Roggli; S D Greenberg
Journal:  Am J Clin Pathol       Date:  1989-11       Impact factor: 2.493

3.  The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval.

Authors:  J R Riera; C Astengo-Osuna; J A Longmate; H Battifora
Journal:  Am J Surg Pathol       Date:  1997-12       Impact factor: 6.394

4.  Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1.

Authors:  M L Warnock; A Stoloff; A Thor
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

5.  MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells.

Authors:  R L Morgan; B R De Young; V R McGaughy; T H Niemann
Journal:  Cancer       Date:  1999-12-25       Impact factor: 6.860

6.  Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies.

Authors:  A Donna; P G Betta; P Chiodera; D Bellingeri; R Libener; F Zorzi; G F Tassi
Journal:  Hum Pathol       Date:  1997-08       Impact factor: 3.466

7.  Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma.

Authors:  J Mezger; R Lamerz; W Permanetter
Journal:  J Thorac Cardiovasc Surg       Date:  1990-12       Impact factor: 5.209

8.  Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.

Authors:  H Moch; M Oberholzer; P Dalquen; W Wegmann; F Gudat
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

9.  Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker.

Authors:  C S Kortsik; P Werner; N Freudenberg; J C Virchow; C Kroegel; M Pott; H Matthys
Journal:  Lung       Date:  1995       Impact factor: 2.584

10.  Environmental malignant mesothelioma in southern Anatolia: a study of fifty cases.

Authors:  E H Zeren; D Gümürdülü; V L Roggli; S Zorludemir; M Erkişi; I Tuncer
Journal:  Environ Health Perspect       Date:  2000-11       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.